Replies to post #236228 on Innovation Pharmaceuticals Inc (IPIX)

[DaubersUP]

Again. MILD psoriasis is going to have extremely higher Placebo rates.
Using an IGA scale with a primary of a greater or equal to 2 point reduction was ridiculous standards. For mild and moderate. Jmo. I think p phase 2b is going to KNOCK the snot out of all you naysayers. Tic toc. Hoping for it this month.

[DesireToLearn]

Then maybe Otezla barely squeezed by?

The ph2a was not designed to have stellar results or to sail by placebo or competition. It was designed to be a challenging trial under extreme conditions, even included those previously unsuccessful in biologics likely to see if the money was worth spending on further development. My guess they wanted to spend on B and K but found P was worth the $ allocation. Turns out signs were that it was worth it. Guses we'll see soon, probably by end of August I would think.

[williamssc]

We should see less of a placebo response in the p2b due to all patients graded moderate to severe.

From P2a study: "Sub-population analyses further showed greater efficacy demonstrated in patients who had a baseline IGA score of 3 (“moderate”) as compared to those with a baseline score of 2 (“mild”). Some of these patients even experienced a 3-point reduction in their IGA score, going from “moderate” to “clear.” This suggests Prurisol may be more effective in treating moderate to severe psoriasis patients to a greater degree than those patients who exhibit less severe symptoms. In moderate to severe psoriasis studies, the placebo response also tends to be lower".